Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05631223 | RECRUITING | Psoriatic Arthritis

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
Sponsor:

University of Pennsylvania

Brief Summary:

This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).

Condition or disease

Psoriatic Arthritis

Intervention/treatment

Telemedicine

Phase

NA

Detailed Description:

The proposed trial will be embedded within clinical care. This is a 2-year interventional trial that will enroll patients with active psoriatic arthritis despite stable therapy among three centers (the University of Pennsylvania, University of Utah, and University of Oxford). The intervention employs PsOWellTM, a program that trains clinicians to utilize motivational interviewing to help patients set goals and make lifestyle/behavior changes for holistic management of psoriasis.

Study Type : INTERVENTIONAL
Estimated Enrollment : 87 participants
Masking : NONE
Masking Description : As a pilot study to understand implementation barriers, assess feasibility, and effectiveness, this study is not blinded or randomized.
Primary Purpose : TREATMENT
Official Title : Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA): Implementation of PsOWellTM in PsA
Actual Study Start Date : 2023-03-10
Estimated Primary Completion Date : 2025-02
Estimated Study Completion Date : 2025-02

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 89 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Population: Patients with Psoriatic Arthritis
  • * Age 18-89.
  • * Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10).
  • * Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit).
  • * Meet CASPAR criteria.
  • * Provision of signed and dated informed consent form.
  • * Willingness to comply with all study procedures and availability for duration of the study.
  • * Has access to a mobile phone or other mobile device.
Exclusion Criteria
  • * Inability to provide informed consent.
  • * Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks.
  • * PsAID score ≤4
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

Location Details

NCT05631223

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Pennsylvania

University Of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

RECRUITING

United States, Utah

University of Utah

Salt Lake City, Utah, United States, 84112